--- title: "These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/274546486.md" description: "Regeneron Pharmaceuticals Inc. reported strong Q4 earnings with adjusted earnings of $11.44 per share, surpassing expectations. Sales reached $3.88 billion, also above consensus. The company forecasts a GAAP gross margin of 79%-80% for fiscal 2026 and adjusted R&D expenses of $5.9-$6.1 billion. Following the earnings report, analysts revised their price targets: Truist lowered to $818, Cantor raised to $800, Wells Fargo to $800, and Morgan Stanley to $769. Regeneron shares rose 2.1% to $756.63." datetime: "2026-02-02T17:13:38.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274546486.md) - [en](https://longbridge.com/en/news/274546486.md) - [zh-HK](https://longbridge.com/zh-HK/news/274546486.md) --- > 支持的语言: [English](https://longbridge.com/en/news/274546486.md) | [繁體中文](https://longbridge.com/zh-HK/news/274546486.md) # These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results **Regeneron Pharmaceuticals Inc**. (NASDAQ:REGN) on Friday reported upbeat fourth-quarter earnings. The company posted adjusted earnings of $11.44 per share, down 5% year-over-year, beating the consensus of $10.71. The company reported sales of $3.88 billion, up 3% year over year, beating the consensus of $3.79 billion. Regeneron expects fiscal 2026 GAAP gross margin of 79%–80%, with adjusted gross margin of 83%–84%. The company forecasts adjusted R&D expenses of $5.9–$6.1 billion in 2026, and non-GAAP SG&A expenditure between $2.5 billion and $2.65 billion. “Regeneron performed well in 2025, with financial strength driven by our four blockbuster medicines and future growth supported by our exciting late-stage clinical portfolio,” said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron. Regeneron Pharmaceuticals shares gained 2.1% to trade at $756.63 on Monday. These analysts made changes to their price targets on Regeneron Pharmaceuticals following earnings announcement. - Truist Securities analyst Gregory Renza maintained Regeneron Pharmaceuticals with a Buy and lowered the price target from $820 to $818. - Cantor Fitzgerald analyst Carter Gould maintained the stock with an Overweight rating and raised the price target from $740 to $800. - Wells Fargo analyst Mohit Bansal maintained Regeneron Pharmaceuticals with an Equal-Weight rating and raised the price target from $745 to $800. - Morgan Stanley analyst Matthew Harrison maintained the stock with an Equal-Weight rating and raised the price target from $768 to $769. **Considering buying REGN stock? Here’s what analysts think:** Photo via Shutterstock ### 相关股票 - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) - [Regeneron Pharma (REGN.US)](https://longbridge.com/zh-CN/quote/REGN.US.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md) - [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) ## 相关资讯与研究 - [Regeneron Gets FDA OK for Extended Eylea HD Dosing](https://longbridge.com/zh-CN/news/281556416.md) - [Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients](https://longbridge.com/zh-CN/news/278381000.md) - [Canada's Perimeter Medical Imaging prelim Q4 revenue jumps 143%](https://longbridge.com/zh-CN/news/281240360.md) - [BUZZ-Context Therapeutics rises as FDA grants fast-track status to ovarian cancer drug](https://longbridge.com/zh-CN/news/281517197.md) - [Eli Lilly Stock (LLY) Surges as FDA Approves Weight-Loss Pill](https://longbridge.com/zh-CN/news/281437997.md)